Basic Information
| Drug ID | DDPD00203 |
|
| Drug Name | Sildenafil | |
| Molecular Weight | 474.576 | |
| Molecular Formula | C22H30N6O4S | |
| CAS Number | 139755-83-2 | |
| SMILES | CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(C)CC1 | |
| External Links | ||
| DRUGBANK | DB00203 | |
| PubChem Compound | 5212 | |
| PDR | 469 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Log P | 1.9 | - | 1.9 | - | DRUGBANK |
| Melting Point | 189.5 | ℃ | 189-190 | ℃ | DRUGBANK |
| Water Solubility | 3500.0 | mg/L | 3.5 | mg/ml | DRUGBANK |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
|---|---|---|---|---|---|---|---|
| Bioavailability | 41.0 | % | ~41 | % | PO, oral; | DRUGBANK | Bioavailability | 44.0 | % | 25-63 | % | PO, oral; | DRUGBANK | Bioavailability | 58.6 | % | 58.63 | % | Oral multiple dose; hypertension; increasing doses; | hypertension ↑ ;increasing doses ↑ ; | DRUGBANK | Bioavailability | 38.0 | % | 38.0 | % | The Pharmacological Basis of Therapeutics |
| C Max | 212.0 | ng/ml | 212±59 | ng/ml | The Pharmacological Basis of Therapeutics | ||
| T Max | 1.3 | h | 0.5-2 | h | PO, oral; | DRUGBANK | T Max | 1.2 | h | 1.2±0.3 | h | The Pharmacological Basis of Therapeutics |
| Clearance | 41.0 | L/h | 41.0 | L/h | Total clearance; | DRUGBANK | Clearance | 0.36 | L/h/kg | 6.0±1.1 | ml/min/kg | hydrolysis; hydrolysis; normal,healthy; Male, men; | Elderly ↓ ;hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ; | The Pharmacological Basis of Therapeutics | Clearance | 0.54 | L/h/kg | 9 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 105.0 | L | ~105 | L | Steady state volume of distribution; | DRUGBANK | Volume of Distribution | 1.2 | L/kg | 1.2±0.3 | L/kg | hydrolysis; hydrolysis; normal,healthy; Male, men; | The Pharmacological Basis of Therapeutics | Volume of Distribution | 1.4 | L/kg | 1.36 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 4.0 | h | ~3-5 | h | terminal half-life; | DRUGBANK | Half-life | 2.4 | h | 2.4±1.0 | h | Male, men; | The Pharmacological Basis of Therapeutics | Half-life | 2.2 | h | 2.2 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Toxicity MRHD | 100.0 | mg | 100.0 | mg | human, homo sapiens; Male, men; | DRUGBANK | |
| Toxicity MTD | 10.0 | mg/kg/day | 10.0 | mg/kg/day | mouse; | DRUGBANK | |
| Eliminate Route | 80.0 | % | ~80 | % | Faeces excretion; PO, oral; | DRUGBANK | Eliminate Route | 13.0 | % | ~13 | % | Urinary excretion; PO, oral; | DRUGBANK | Eliminate Route | 0 | % | 0 | % | Urinary excretion; Male, men; normal,healthy; human, homo sapiens; Unchanged drug; | The Pharmacological Basis of Therapeutics |
| Protein Binding | 96.0 | % | 96 | % | Male, men; normal,healthy; human, homo sapiens; | The Pharmacological Basis of Therapeutics |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Frequency | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|---|
| Max dose for neonates | 3.0 | mg/kg/day | 1 | mg/kg/dose | PO, oral | q8h | Revatio | sildenafil | PDR |
| Max dose for neonates | 0.4 | mg/kg/dose | 0.4 | mg/kg/dose | intravenous injection, IV | Revatio | sildenafil | PDR | |
| Max dose for neonates | 0.00279166666666667 | mg/kg/day | 0.067 | mg/kg/hour | intravenous infusion, iv in drop | Revatio | sildenafil | PDR | |
| Max dose for infants | 3.0 | mg/kg/day | 1 | mg/kg/dose | PO, oral | q8h | Revatio | sildenafil | PDR |
| Max dose for children | 20.0 | mg | 20 | mg | PO, oral | tid | Revatio | sildenafil | PDR |
| Max dose for children | 10.0 | mg | 10 | mg | PO, oral | tid | Revatio | sildenafil | PDR |
| Max dose for adolescents | 20.0 | mg | 20 | mg | PO, oral | tid | Revatio | sildenafil | PDR |
| Max dose for adults | 100.0 | mg/day | 100 | mg/day | PO, oral | Revatio | sildenafil | PDR | |
| Max dose for adults | 60.0 | mg/day | 60 | mg/day | PO, oral | Revatio | sildenafil | PDR | |
| Max dose for adults | 30.0 | mg/day | 30 | mg/day | intravenous injection, IV | Revatio | sildenafil | PDR | |
| Max dose for adults | 240.0 | mg/day | 240 | mg/day | PO, oral | Revatio | sildenafil | PDR | |
| Max dose for geriatric | 100.0 | mg/day | 100 | mg/day | PO, oral | Revatio | sildenafil | PDR | |
| Max dose for geriatric | 60.0 | mg/day | 60 | mg/day | PO, oral | Revatio | sildenafil | PDR | |
| Max dose for geriatric | 30.0 | mg/day | 30 | mg/day | intravenous injection, IV | Revatio | sildenafil | PDR | |
| Max dose for geriatric | 240.0 | mg/day | 240 | mg/day | PO, oral | Revatio | sildenafil | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1